BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34725737)

  • 1. How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.
    Cao S; Jiang X; Tan C; Fu M; Xiong W; Ji D; Lv J
    J Mol Model; 2021 Nov; 27(11):337. PubMed ID: 34725737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
    Terzyan SS; Shen T; Liu X; Huang Q; Teng P; Zhou M; Hilberg F; Cai J; Mooers BHM; Wu J
    J Biol Chem; 2019 Jul; 294(27):10428-10437. PubMed ID: 31118272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multikinase inhibitors in thyroid cancer.
    Licitra L; Locati LD
    Ann Oncol; 2012 Sep; 23 Suppl 10():x328-33. PubMed ID: 22987985
    [No Abstract]   [Full Text] [Related]  

  • 4. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
    Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
    J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations.
    Cao S; Tan C; Fei A; Hu G; Fu M; Lv J
    J Mol Model; 2022 Dec; 29(1):24. PubMed ID: 36576611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of wild-type and mutated RET proto- oncogene associated with familial medullary thyroid cancer.
    Masbi MH; Mohammadiasl J; Galehdari H; Ahmadzadeh A; Tabatabaiefar MA; Golchin N; Haghpanah V; Rahim F
    Asian Pac J Cancer Prev; 2014; 15(5):2027-33. PubMed ID: 24716929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
    Gorla L; Mondellini P; Cuccuru G; Miccichè F; Cassinelli G; Cremona M; Pierotti MA; Lanzi C; Bongarzone I
    Mol Carcinog; 2009 Mar; 48(3):220-231. PubMed ID: 18756447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Familial medullary thyroid carcinoma: case report and literature review.].
    Barletta Carrillo CF; Poterico Rojas JA; Barrionuevo Cornejo C; Casavilca Zambrano S; Pinedo Cárdenas A; Quispe Santibañez I; Castro Mujica MDC
    Rev Fac Cien Med Univ Nac Cordoba; 2018 Dec; 75(4):303-309. PubMed ID: 30734711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea.
    Jung KY; Kim SM; Kim MJ; Cho SW; Kim BW; Lee YS; Jeong JJ; Nam KH; Chung WY; Lee KE; Chung EJ; Kim HJ; Park DJ; Sung MW; Park CS; Cho BY; Park YJ; Chang HS
    Surgery; 2018 Aug; 164(2):312-318. PubMed ID: 29779869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Krampitz GW; Norton JA
    Cancer; 2014 Jul; 120(13):1920-31. PubMed ID: 24699901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Case of Hereditary Medullary Thyroid Cancer (MEN2A/FMTC) Diagnosed at the Time of Recurrence].
    Enomoto K; Shimizu K; Hirose M; Miyabe H; Morizane N; Takenaka Y; Shimazu K; Fushimi H; Uno A
    Nihon Jibiinkoka Gakkai Kaiho; 2015 Mar; 118(3):219-23. PubMed ID: 26349338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.
    Pelizzo MR; Torresan F; Boschin IM; Nacamulli D; Pennelli G; Barollo S; Rubello D; Mian C
    Am J Clin Oncol; 2015 Oct; 38(5):508-13. PubMed ID: 24064755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
    Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene.
    Peppa M; Boutati E; Kamakari S; Pikounis V; Peros G; Panayiotides IG; Economopoulos T; Raptis SA; Hadjidakis D
    Eur J Endocrinol; 2008 Dec; 159(6):767-71. PubMed ID: 18805915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
    Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
    Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
    Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
    Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.